S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
The 3-Stock Retirement Blueprint (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
The 3-Stock Retirement Blueprint (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
The 3-Stock Retirement Blueprint (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
The 3-Stock Retirement Blueprint (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
The 3-Stock Retirement Blueprint (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
The 3-Stock Retirement Blueprint (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
The 3-Stock Retirement Blueprint (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
The 3-Stock Retirement Blueprint (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
NASDAQ:CAPR

Capricor Therapeutics - CAPR Stock Forecast, Price & News

$4.12
+0.04 (+0.98%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.05
$4.20
50-Day Range
$3.87
$6.55
52-Week Range
$2.56
$6.58
Volume
84,918 shs
Average Volume
137,534 shs
Market Capitalization
$103.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.50

Capricor Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
300.5% Upside
$16.50 Price Target
Short Interest
Healthy
1.03% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.29mentions of Capricor Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.21) to ($0.79) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

626th out of 1,027 stocks

Pharmaceutical Preparations Industry

296th out of 503 stocks

CAPR stock logo

About Capricor Therapeutics (NASDAQ:CAPR) Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Receive CAPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CAPR Stock News Headlines

Capricor Therapeutics
Earnings Scheduled For November 10, 2022
Capricor Therapeutics, Inc. (CAPR)
Finalist: Anthony J. Bergmann
See More Headlines
Receive CAPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CAPR Company Calendar

Last Earnings
11/08/2021
Today
12/07/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/09/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CAPR
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.50
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+300.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-20,020,000.00
Pretax Margin
-1,726.70%

Debt

Sales & Book Value

Annual Sales
$250,000.00
Book Value
$1.30 per share

Miscellaneous

Free Float
22,969,000
Market Cap
$103.99 million
Optionable
Not Optionable
Beta
4.18

Key Executives

  • Frank I. Litvack M.D. (Age 59)
    Independent Executive Chairman of the Board
  • Linda Marban Ph.D. (Age 51)
    President, Chief Executive Officer, Director
  • Anthony Bergmann (Age 32)
    Chief Financial Officer, Principal Accounting Officer
  • Karen G. Krasney J.D. (Age 62)
    Executive Vice President, General Counsel
  • Thomas Lyle Copmann Ph.D. (Age 61)
    Vice President - Regulatory Affairs and Drug Development
  • Houman Hemmati M.D.
    Ph.D., Vice President - Medical & Clinical Development, New Therapies
  • Luis Rodriguez-Borlado Ph.D.
    Vice President - Regenerative Therapies
  • Rachel Smith Ph.D. (Age 36)
    Vice President - Research & Development
  • Deborah Ascheim M.D.
    Chief Medical Officer
  • Joshua A. Kazam (Age 40)
    Director













CAPR Stock - Frequently Asked Questions

Should I buy or sell Capricor Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CAPR shares.
View CAPR analyst ratings
or view top-rated stocks.

What is Capricor Therapeutics' stock price forecast for 2023?

2 equities research analysts have issued 1-year price objectives for Capricor Therapeutics' shares. Their CAPR share price forecasts range from $15.00 to $18.00. On average, they predict the company's share price to reach $16.50 in the next twelve months. This suggests a possible upside of 300.5% from the stock's current price.
View analysts price targets for CAPR
or view top-rated stocks among Wall Street analysts.

How have CAPR shares performed in 2022?

Capricor Therapeutics' stock was trading at $2.93 at the beginning of 2022. Since then, CAPR shares have increased by 40.6% and is now trading at $4.12.
View the best growth stocks for 2022 here
.

Are investors shorting Capricor Therapeutics?

Capricor Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 260,600 shares, an increase of 5.3% from the October 31st total of 247,500 shares. Based on an average daily trading volume, of 192,600 shares, the short-interest ratio is currently 1.4 days.
View Capricor Therapeutics' Short Interest
.

When is Capricor Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our CAPR earnings forecast
.

How were Capricor Therapeutics' earnings last quarter?

Capricor Therapeutics Inc (NASDAQ:CAPR) posted its earnings results on Monday, November, 8th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.05. During the same period in the prior year, the firm earned ($0.20) EPS.

What other stocks do shareholders of Capricor Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Capricor Therapeutics investors own include Marinus Pharmaceuticals (MRNS), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Trevena (TRVN), Dynavax Technologies (DVAX), Chesapeake Energy (CHKAQ), OPKO Health (OPK) and Advanced Micro Devices (AMD).

What is Capricor Therapeutics' stock symbol?

Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."

Who are Capricor Therapeutics' major shareholders?

Capricor Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.64%), BlackRock Inc. (1.73%), Dimensional Fund Advisors LP (0.67%), Citadel Advisors LLC (0.00%), Simplex Trading LLC (0.00%) and Bailard Inc. (0.14%). Insiders that own company stock include David B Musket and Xavier Avat.
View institutional ownership trends
.

How do I buy shares of Capricor Therapeutics?

Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Capricor Therapeutics' stock price today?

One share of CAPR stock can currently be purchased for approximately $4.12.

How much money does Capricor Therapeutics make?

Capricor Therapeutics (NASDAQ:CAPR) has a market capitalization of $103.99 million and generates $250,000.00 in revenue each year. The biotechnology company earns $-20,020,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis.

How can I contact Capricor Therapeutics?

Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The official website for the company is www.capricor.com. The biotechnology company can be reached via phone at 310-358-3200, via email at kimberly@argotpartners.com, or via fax at 415-875-7075.

This page (NASDAQ:CAPR) was last updated on 12/8/2022 by MarketBeat.com Staff